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Antiinﬂammatory eggs
 
Proteins secreted by parasite eggs might hold 
the key to the next antiinflammatory therapy. On 
page 1319, Smith and colleagues describe the first 
chemokine binding protein (CKBP) produced by a 
human pathogen and show that it can suppress 
acute inflammation in disease models.
The blood-dwelling worm 
 
Schistosoma mansoni
 
 
takes advantage of the host’s immune system in two 
ways. It subverts specific inflammatory cells to help 
move its eggs from the intestinal vasculature to the 
feces, where they can be shed. It also suppresses the 
immune response in order to establish chronic 
infections, in part as shown here by keeping other 
inflammatory cells away from the eggs.
This selective cell recruitment was not due 
solely to cytokine modulation, a known 
schistosome ability. As viruses produce chemokine 
binding proteins to neutralize host chemokines, 
the authors investigated whether 
 
S. mansoni
 
 
might also make a chemokine binding protein to 
mask the eggs from strong inflammation.
Smith and colleagues now identify a novel 
CKBP (smCKBP) that is secreted from schistosome 
eggs. This protein bound to the chemokines CXCL8 
and CCL3 and prevented them from binding to 
their receptors on immune cells. Injecting mice 
with recombinant smCKBP blocked chemokine-
mediated neutrophil infiltration in response to a 
variety of inflammatory stimuli. This treatment, 
however, had no effect on chronic inflammation 
disorders such as arthritis.
The authors suggest that, in nature, the 
parasite eggs secrete smCKBP to keep neutrophils 
and macrophages out of the surrounding 
granuloma so as not to attract immune attention, 
but pinning this mechanism down will require 
further study. Already tolerated by infected 
humans, smCKBP holds great potential as a new 
therapy for acute inflammatory diseases, especially 
those caused by neutrophilia. 
A schistosome egg secretes chemokine binding protein 
(brown) to ward off immune cells.
 
A plague of deubiquitination
 
Plague bacteria inject infected host cells with a ubiquitin-chopping enzyme, 
according to Zhou and colleagues in a study on page 1327. The group shows that the 
virulence factor YopJ operates as a deubiquitinase to shut down multiple signaling 
pathways that would otherwise help trigger an inflammatory immune response.
Pathogenic 
 
Yersinia
 
 bacteria need the cysteine protease YopJ to kill infected 
macrophages and promote systemic infection in mice. YopJ’s activity somehow 
inhibits pro-inflammatory NF-
 
 
 
B signaling. Previous work by others had shown 
that YopJ can catalyze the removal of the ubiquitin-like protein SUMO-1 from 
cellular proteins. That work proposed that YopJ might desumolyate upstream 
activators of NF-
 
 
 
B.
Here, the authors show that YopJ does not act as a SUMO-1 isopeptidase, but 
rather as a deubiquitinase. YopJ stripped the ubiquitin chains from the adaptor 
molecules TRAF2 and TRAF6, which need these modifications to help activate 
NF-
 
 
 
B signaling, and also from the NF-
 
 
 
B inhibitor protein I
 
 
 
B. Ubiquitination of 
I
 
 
 
B normally tags the inhibitor for proteasomal degradation, thus allowing NF-
 
 
 
B 
to move into the nucleus and activate inflammatory genes.
YopJ could clip ubiquitin molecues attached either by their lysine 63 residue (as 
on the TRAF proteins) or by their lysine 48 residue (as on I
 
 
 
B). YopJ’s deubiquitinating 
“promiscuity,” the authors write, allows the bacteria to simultaneously shut off 
multiple routes of NF-
 
 
 
B activation and thus to avoid immune attack. YopJ-related 
proteins exist in a diverse variety of bacterial pathogens, indicating that encoding 
deubiquitinases may be a common immune evasion tactic. 
 
Toll-free autoimmunity
 
Self-DNA and pathogen-derived DNA take different routes to immune
activation, say Okabe and colleagues (page 1333). Thus, it may be possible
to block an autoimmune response to self-DNA without compromising
the beneficial response to pathogenic DNA.
Microbial DNA is mopped up by macrophages and dendritic cells,
which get activated via Toll-like receptors (TLRs), resulting in the
production of interferon-
 
 
 
 (IFN
 
 
 
). Recent studies have shown that
mammalian DNA complexed to antibodies can also trigger IFN
 
 
 
 pro-
duction via a TLR (specifically TLR9).
The immune system can also be activated by naked self-DNA, leading
to some autoimmune diseases. One such state occurs in mice lacking
DNaseII. These mice accumulate undigested self-DNA from dead cells in
their macrophages, and act as a model for systemic lupus erythematosus
(SLE), a disease characterized by autoantibodies to circulating self-DNA.
The up-regulation of IFN
 
 
 
 in these
mice kills precursor red blood cells, induces
severe anemia, and causes the observed
embryonic lethality. A DNaseII-IFN re-
ceptor double knock-out rescued these
effects. In the current study, however, the
DNaseII
 
 
 
 phenotype, including the IFN
 
 
 
up-regulation, is not rescued by knock-
out of TLR9, TLR3, or their adaptor
molecules MyD88 and TRIF.
The results imply that a TLR-independent
pathway of IFN activation exists. Therefore, it
may be possible to block that autoimmune
response pathway while leaving the TLR-
dependent response to pathogens intact. 
Self-DNA (blue) activates 
DNaseII-deficient macro-
phages via a unique pathway.
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